US biotech Epizyme is gearing up for a potentially lucrative second indication for its Tazverik (tazemetostat), after the FDA agreed to a fast review in follicular lymphoma. A first-in-class EZH2 ...

By April 7, 2022, Gupta knew the cancer drug and assets Ipsen wanted to acquire belonged to Cambridge-based biotech Epizyme, the maker of the cancer medication Tazverik, prosecutors said.

Epizyme is developing tazemetostat, a first-in-class EZH2 inhibitor, for several types of blood cancer and genetically defined solid tumours. Epizyme holds global development and commercialisation ...